Abstract

Increasing resistance to antibiotics and the challenges in developing new bactericidal agents against novel essential targets is fueling interest in alternative approaches to antibacterial thereapy. One approach is to target inhibition of virulence factors required for bacterial pathogenesis but which are not essential for bacterial growth per se. This talk will explore the concepts of antivirulence therapy and discuss opportunities for development of Pseudomonas aeruginosa elastase inhibitors as antivirulence agents.